All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results VERU-111, 2022 0.30 [0.14; 0.64]
0.30 [0.14 ; 0.64 ] VERU-111, 2022 1 0% 150 NA not evaluable death D28detailed results Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gunst JD, 2021 0.99 [0.29; 3.42]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.71 [0.35 ; 1.45 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022 3 64% 15,285 moderate not evaluable death or transfer to ICUdetailed results Gunst JD, 2021 0.55 [0.26; 1.17]
0.55 [0.26 ; 1.17 ] Gunst JD, 2021 1 0% 205 NA not evaluable deathsdetailed results Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gunst JD, 2021 0.70 [0.20; 2.49]
Nouri-Vaskeh, 2021 0.35 [0.06; 1.91]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.62 [0.32 ; 1.19 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Nouri-Vaskeh, 2021, RECOVERY (Aspirin), 2022 4 58% 15,368 moderate not evaluable deaths (time to event analysis only)detailed results Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Gunst JD, 2021 0.70 [0.20; 2.49]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
0.66 [0.32 ; 1.36 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, RECOVERY (Aspirin), 2022 3 66% 15,288 moderate not evaluable clinical improvementdetailed results Gunst JD, 2021 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] Gunst JD, 2021 1 0% 208 NA not evaluable clinical improvement (time to event analysis only)detailed results Gunst JD, 2021 1.14 [0.83; 1.57]
1.14 [0.83 ; 1.57 ] Gunst JD, 2021 1 0% 208 NA not evaluable death or ventilationdetailed results Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
0.46 [0.22 ; 0.96 ] Fragoso-Saavedra (PISCO), 2020 1 0% 188 NA not evaluable hospital dischargedetailed results Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
1.06 [1.02 ; 1.10 ] Fragoso-Saavedra (PISCO), 2020, RECOVERY (Aspirin), 2022 2 0% 15,080 moderate not evaluable mechanical ventilationdetailed results Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gunst JD, 2021 2.27 [0.62; 8.26]
1.32 [0.50 ; 3.45 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021 2 21% 393 moderate not evaluable mechanical ventilation (time to event analysis only)detailed results Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Gunst JD, 2021 0.69 [0.14; 3.42]
0.77 [0.31 ; 1.90 ] Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021 2 0% 396 moderate not evaluable ICU admissiondetailed results Gunst JD, 2021 0.80 [0.34; 1.90]
0.80 [0.34 ; 1.90 ] Gunst JD, 2021 1 0% 205 NA not evaluable recoverydetailed results Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
Gunst JD, 2021 1.18 [0.87; 1.61]
1.03 [0.58 ; 1.84 ] Crippa (CANDIDATE), 2021, Gunst JD, 2021 2 26% 299 moderate not evaluable serious adverse eventsdetailed results Gunst JD, 2021 1.84 [0.79; 4.30]
1.84 [0.79 ; 4.30 ] Gunst JD, 2021 1 0% 205 NA not evaluable adverse eventsdetailed results Gunst JD, 2021 0.80 [0.43; 1.51]
0.80 [0.43 ; 1.51 ] Gunst JD, 2021 1 0% 205 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-10 15:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
